Clinical trial
Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation
NCT00286624 · University of Minnesota, Other · Completed
Key facts
| NCT number | NCT00286624 |
|---|---|
| Title | Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation |
| Official title | A One-Year, Single-Center, Prospective, Open-Label Study of the Safety, Tolerability, and Preliminary Efficacy of Anti-Thymocyte Globulin, Cyclosporine, and RAD in Type 1 Diabetic Islet Transplant Recipients |
| Acronym | NITA |
| Lead sponsor | University of Minnesota, Other |
| Collaborators | Juvenile Diabetes Research Foundation National Institutes of Health (NIH) NIH Novartis Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Type 1 Diabetes Mellitus, Hypoglycemia |
| Intervention type | Biological, Drug |
| Interventions | Allogeneic Islets of Langerhans, Everolimus, anti-thymocyte globulin, Cyclosporine |
| Enrollment | 6 |
| Start date | Mar 1, 2003 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Feb 3, 2006 |
| Last update posted | May 8, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: